HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

503.398

-20.475-3.91%

Number of Gainers:8

Number of Losers:24

Number of Flat:1

PE:- -

High:523.582

Open:523.582

Low:498.297

Close:523.873

Volume:119.87M

Turnover:3.20B

Market Cap:322.68B

Float Cap:286.07B

Loading ...

Zhaoke Ophthalmology's Half-Year Results: Net Loss Widens to RMB 123 Million Amid Rising Costs

China's Ocumension Therapeutics H1 Revenue Surges on Higher Ophthalmic Product Sales

Ocumension Therapeutics Shifts Hk$102.5 Million IPO Proceeds to Working Capital, General Corporate Uses

Ocumension Therapeutics FY26 H1 Net Loss Narrows 25.2% to RMB 99.02 Million; Revenue Rises 44.1% to RMB 423.7 Million

Ocumension Therapeutics - Board Does not Recommend Distribution of an Interim Dividend

THOMSON REUTERS

Ocumension Therapeutics - Adjusted Net Loss Narrowed by 46.7% to Rmb57.5 Mln for Six Months

THOMSON REUTERS

Alphamab Oncology - Board Resolves to Repurchase Shares up to HK$80 Mln in Value

THOMSON REUTERS

Alphamab Oncology Launches On-Market Share Buyback of up to HK$ 80 Million

EDDING GENOR Reports Interim Loss, Swinging to Deficit in First Half

China's Zhaoke Ophthalmology H1 Revenue Rises

Suzhou Basecare FY26 H1 Net Loss Narrows 40.7% to RMB 72.05 Million; Revenue Rises 27% to RMB 128.75 Million

Zhaoke Ophthalmology FY26 H1 Loss Widens to RMB 122.59 Million; Revenue Rises 19.14% to RMB 18.83 Million

Mabpharm FY26 H1 Profit More than Doubled to RMB 31.36 Million; Revenue Rises 45.1% to RMB 397.94 Million

Edding Genor Swings to FY26 H1 Net Loss of RMB 65.88 Million; Revenue Falls 23.1% to RMB 872.73 Million

Domestic Innovative Drug Sector Shifts From Cash Burn to Profit Generation as Mid-Year Reports Roll In

ZyLoxTB Allocates HK$1.16M to Buy Back 53,000 Shares on August 28

CStone Pharmaceuticals (SEHK:2616) Stock Price Reflects Growth While Losses Stay Heavy

Simply Wall St.

Zylox-Tonbridge Files HKEX Next-Day Disclosure Return Reporting Share Repurchase at HKD 21.78-22.2

Alphamab Oncology (SEHK:9966) Stock Rally Meets Revenue Dip And Losses

Simply Wall St.

Goldman Sachs Lifts Innocare Price Target to HK$22.71 on Robust Orelabrutinib Sales

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/BK1574/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":503.39795,"timestamp":1788163726135,"preClose":523.8731,"halted":0,"volume":119868273,"delay":0,"changeRate":-0.039084,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-20.475159,"latestTime":"08-31 16:00:00","open":523.582,"high":523.582,"low":498.29733,"amount":3203299214.5,"amplitude":0.048265,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"pbRate":3.909696,"peRate":137.956161,"turnoverRate":0.003654,"increases":8,"decrements":24,"flats":1,"marketCap":322680201168,"floatMarketCap":286067329608},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":523.582,"amplitude":0.048265,"preClose":523.8731,"low":498.29733,"pbRate":"3.909696","latestPrice":503.39795,"volume":119868273,"delay":0,"open":523.582,"prevYearClose":556.26263,"prevWeekClose":523.873,"prevMonthClose":473.313,"prevQuarterClose":453.519,"fiveDayClose":496.742,"twentyDayClose":467.18,"sixtyDayClose":475.465,"secType":"PLATE","market":"HK","turnoverRate":0.003654,"peRate":137.956161,"marketCap":322680201168,"floatMarketCap":286067329608,"timestamp":1788163726135,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":8,"down":24,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1143245213","title":"Zhaoke Ophthalmology's Half-Year Results: Net Loss Widens to RMB 123 Million Amid Rising Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=1143245213","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143245213?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:53","pubTimestamp":1787928836,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology-B (06622) has released its interim results for the 2026 fiscal year, showing total revenue of RMB 18.828 million, a year-on-year increase of 19.14%. However, the company recorded...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","06622","BK1191","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662099200","title":"China's Ocumension Therapeutics H1 Revenue Surges on Higher Ophthalmic Product Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2662099200","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662099200?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:24","pubTimestamp":1787927067,"startTime":"0","endTime":"0","summary":"China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product salesOverviewChina ophthalmic pharma firm's half-year revenue rose 44.1% yr/yr to RMB423.7 mlnAdjusted net loss narrowed ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL1N44P0NI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","01477","06622","BK1209","BK1191","02219","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662099255","title":"Ocumension Therapeutics Shifts Hk$102.5 Million IPO Proceeds to Working Capital, General Corporate Uses","url":"https://stock-news.laohu8.com/highlight/detail?id=2662099255","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662099255?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:21","pubTimestamp":1787926882,"startTime":"0","endTime":"0","summary":"Ocumension Therapeutics shifts HK$102.5 million IPO proceeds to working capital, general corporate usesOcumension shifted capital planning toward broader commercial operations, reallocating remaining ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL60mWRN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662099986","title":"Ocumension Therapeutics FY26 H1 Net Loss Narrows 25.2% to RMB 99.02 Million; Revenue Rises 44.1% to RMB 423.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662099986","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662099986?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:15","pubTimestamp":1787926549,"startTime":"0","endTime":"0","summary":"Ocumension Therapeutics FY26 H1 net loss narrows 25.2% to RMB 99.02 million; revenue rises 44.1% to RMB 423.7 millionOcumension Therapeutics revenue rose 44.1% to RMB 423.7 million for the six months ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDLbKvvMw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662999470","title":"Ocumension Therapeutics - Board Does not Recommend Distribution of an Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2662999470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662999470?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:15","pubTimestamp":1787926532,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44P1VM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662099671","title":"Ocumension Therapeutics - Adjusted Net Loss Narrowed by 46.7% to Rmb57.5 Mln for Six Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2662099671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662099671?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:15","pubTimestamp":1787926532,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44P1VM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662096191","title":"Alphamab Oncology - Board Resolves to Repurchase Shares up to HK$80 Mln in Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2662096191","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662096191?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:56","pubTimestamp":1787925376,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44P1XZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662509616","title":"Alphamab Oncology Launches On-Market Share Buyback of up to HK$ 80 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662509616","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662509616?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:55","pubTimestamp":1787925346,"startTime":"0","endTime":"0","summary":"Alphamab Oncology launches on-market share buyback of up to HK$ 80 millionAlphamab Oncology authorized an on-market share buyback of up to HK$80 million, starting Aug. 28, 2026.Repurchases will be fun","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL21zqMG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171474901","title":"EDDING GENOR Reports Interim Loss, Swinging to Deficit in First Half","url":"https://stock-news.laohu8.com/highlight/detail?id=1171474901","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171474901?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:50","pubTimestamp":1787925016,"startTime":"0","endTime":"0","summary":"EDDING GENOR (06998) has announced its financial results for the six-month period ended June 30, 2026, revealing a notable shift from profitability to a net loss.During the reporting period, the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","06998","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662951720","title":"China's Zhaoke Ophthalmology H1 Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2662951720","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662951720?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:24","pubTimestamp":1787923484,"startTime":"0","endTime":"0","summary":"China's Zhaoke Ophthalmology H1 revenue risesOverviewChina ophthalmic drug maker's interim revenue rose yr/yr to RMB 18.8 mlnNon-HKFRS adjusted loss for the period widened slightly to RMB 116.1 mlnCom","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL1N44P0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1209","BK1589","BK1191","BK1583","03692","BK1574","BK1161","02219","02616","BK1587","06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662951250","title":"Suzhou Basecare FY26 H1 Net Loss Narrows 40.7% to RMB 72.05 Million; Revenue Rises 27% to RMB 128.75 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662951250","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662951250?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:23","pubTimestamp":1787923391,"startTime":"0","endTime":"0","summary":"Suzhou Basecare FY26 H1 net loss narrows 40.7% to RMB 72.05 million; revenue rises 27% to RMB 128.75 millionSuzhou Basecare posted revenue of RMB 128.75 million for the six months ended June 30, 2026,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL9lJSRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170","BK1574","BK1597","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662696095","title":"Zhaoke Ophthalmology FY26 H1 Loss Widens to RMB 122.59 Million; Revenue Rises 19.14% to RMB 18.83 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662696095","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662696095?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:16","pubTimestamp":1787923002,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology FY26 H1 loss widens to RMB 122.59 million; revenue rises 19.14% to RMB 18.83 millionZhaoke Ophthalmology posted revenue of RMB 18.83 million, up 19.14% for the six months ended Ju","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL4x0NrM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","BK1191","BK1583","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662409300","title":"Mabpharm FY26 H1 Profit More than Doubled to RMB 31.36 Million; Revenue Rises 45.1% to RMB 397.94 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662409300","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662409300?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:05","pubTimestamp":1787922358,"startTime":"0","endTime":"0","summary":"Mabpharm FY26 H1 profit more than doubled to RMB 31.36 million; revenue rises 45.1% to RMB 397.94 millionMabpharm posted a swing to profit, with attributable earnings of RMB 31.36 million, versus RMB ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDLc92Mfg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02181","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662098078","title":"Edding Genor Swings to FY26 H1 Net Loss of RMB 65.88 Million; Revenue Falls 23.1% to RMB 872.73 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662098078","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662098078?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:40","pubTimestamp":1787920807,"startTime":"0","endTime":"0","summary":"Edding Genor swings to FY26 H1 net loss of RMB 65.88 million; revenue falls 23.1% to RMB 872.73 millionEdding Genor posted a net loss of RMB 65.88 million, swinging from profit in the year-earlier per","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL71J8MG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","06998","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126390441","title":"Domestic Innovative Drug Sector Shifts From Cash Burn to Profit Generation as Mid-Year Reports Roll In","url":"https://stock-news.laohu8.com/highlight/detail?id=1126390441","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126390441?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:30","pubTimestamp":1787920254,"startTime":"0","endTime":"0","summary":"As August draws to a close, the release of mid-year reports from innovative drug companies is accelerating, drawing heightened attention to the sector. How did domestic innovative drug developers...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","BK1161","LNGR","06978","IBBQ","MEDX","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174722178","title":"ZyLoxTB Allocates HK$1.16M to Buy Back 53,000 Shares on August 28","url":"https://stock-news.laohu8.com/highlight/detail?id=1174722178","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174722178?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:28","pubTimestamp":1787920091,"startTime":"0","endTime":"0","summary":"ZYLOXTB (02190) announced on August 28 that it spent HK$1.163 million to repurchase 53,000 shares of its own stock.According to the company's statement, the buyback transaction was executed on the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1587","02190","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662933470","title":"CStone Pharmaceuticals (SEHK:2616) Stock Price Reflects Growth While Losses Stay Heavy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662933470","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662933470?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:26","pubTimestamp":1787919973,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals came into this print with its stock up 35.4% over the past month and another move to HK$5.89 into the close on 28 August. That price action reflects a growth story that investors already know is not yet profitable. The headline from these half year numbers is the size of the earnings hole. CStone reported a net loss of ¥252.3m for H1 2026 and trailing 12 month losses from continuing operations of ¥419.1m. The market is paying up for forecast growth while the income...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-stock-price-reflects-growth","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-stock-price-reflects-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02616","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662060331","title":"Zylox-Tonbridge Files HKEX Next-Day Disclosure Return Reporting Share Repurchase at HKD 21.78-22.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2662060331","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662060331?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:50","pubTimestamp":1787917803,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge files HKEX next-day disclosure return reporting share repurchase at HKD 21.78-22.2Zylox-Tonbridge filed an HKEX next-day disclosure return showing a repurchase of 53,000 H shares on Au","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDLrVW9h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02190","BK1100","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662935380","title":"Alphamab Oncology (SEHK:9966) Stock Rally Meets Revenue Dip And Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2662935380","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662935380?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:32","pubTimestamp":1787916728,"startTime":"0","endTime":"0","summary":"Alphamab Oncology stock has been on a short run higher, with the shares up about 15% over the past month. However, today’s earnings send a very different message. The headline is simple: revenue for the first half of 2026 came in at ¥271.2m, while the company reported a net loss of ¥40.5m and a basic loss per share of ¥0.04.\nFor a biotech that still trades on revenue potential more than profit, this contrast between top line and continuing losses is what the market is really reacting to. The...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/alphamab-oncology-sehk9966-stock-rally-meets-revenue-dip-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/alphamab-oncology-sehk9966-stock-rally-meets-revenue-dip-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VOTE","PMDE","RGLO","09966","DECU","BK1574","BK1161","FEBU","GXDW","VGFPF","JOYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163785274","title":"Goldman Sachs Lifts Innocare Price Target to HK$22.71 on Robust Orelabrutinib Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=1163785274","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163785274?lang=en_us&edition=fundamental","pubTime":"2026-08-28 16:40","pubTimestamp":1787906422,"startTime":"0","endTime":"0","summary":"Goldman Sachs has released a research report raising its earnings per share forecasts for INNOCARE (09969) for the 2026 to 2028 period, from 0.15, 0.05, and 0.32 yuan to 0.16, 0.08, and 0.37 yuan,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE0002270589.USD","IE00B19Z3581.USD","LU1144417596.USD","LU1894683264.USD","688428","LU0096364046.USD","09969","LU0106831901.USD","LU1804176565.USD","LU1868836757.USD","LU1894683348.USD","LU2237438978.USD","LU0742534661.SGD","LU0868494617.USD","LU0345770308.USD","BK1161","IE00B19Z3B42.SGD","LU2237443895.HKD","LU1868837300.USD","LU2237443978.SGD","LU2265009873.SGD","BK0239","IE00BFXG1179.USD","LU1791807156.HKD","GS","LU1868837136.USD","EWH","LU1868836914.USD","BK4127","BK4550","IE0034235188.USD","LU0868494708.USD","LU0345770993.USD","BK4588","LU2237443382.USD","LU0942090050.USD","LU2237443465.HKD","LU2237443622.USD","IE00BSNM7G36.USD","LU0251142724.SGD","LU2471134879.HKD","IE0004086264.USD","LU2471134796.USD","LU2750360997.AUD","BK1574","LU2237443549.SGD","BK4504","LU0210536198.USD","BK4533","LU2471134952.CNY","LU2896262040.SGD","IE0004091025.USD","LU0048573561.USD","GSX","BK4516","LU2471134523.USD","LU0061475181.USD","BK4552","LU0251131958.USD","LU2750360641.GBP","LU1868836591.USD","LU1668664300.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":2,"totalSize":352,"code":"91000000","status":"200"}]}}